Home › Clear-cell metastatic renal cell carcinoma
Clear-cell metastatic renal cell carcinoma clinical trials recruiting in the U.S.
17 studies for Clear-cell metastatic renal cell carcinoma are recruiting participants at sites across the United States.
Cities with the most studies
- Baldwin Park, CA7 studies
- New York City, NY5 studies
- Nashville, TN5 studies
- Dallas, TX5 studies
- St. Louis, MO4 studies
- Waukegan, IL4 studies
- Rochester, MN4 studies
- Cleveland, OH3 studies
- Phoenix, AZ3 studies
- San Diego, CA3 studies
- Boston, MA3 studies
- Portland, OR3 studies
- Omaha, NE3 studies
- Irvine, CA3 studies
- Jacksonville, FL3 studies
- Orlando, FL3 studies
- Houston, TX3 studies
- Queens, NY3 studies
- Philadelphia, PA3 studies
- Ann Arbor, MI3 studies
- San Francisco, CA3 studies
By state
- Arizona4 studies
- Arkansas3 studies
- California9 studies
- Florida4 studies
- Illinois5 studies
- Massachusetts4 studies
- Michigan4 studies
- Minnesota5 studies
- Missouri4 studies
- Nebraska3 studies
- New Jersey3 studies
- New York6 studies
- Ohio3 studies
- Oregon3 studies
- Pennsylvania4 studies
- South Carolina4 studies
- Tennessee6 studies
- Texas6 studies
- Virginia3 studies
- Washington3 studies
Recently updated studies
Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 29, 2026 · NCT07011719Casdatifan for the Treatment of Refractory Metastatic Clear Cell Renal Cell Carcinoma
RecruitingPhase 1
Ages 18 to 100 · All sexes · Updated Sep 25, 2026 · NCT07748988Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 17, 2026 · NCT07227415Genetic Testing to Select Therapy for the Treatment of Advanced or Metastatic Kidney Cancer, OPTIC RCC Study
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Aug 19, 2026 · NCT05361720A First-in-Human Study of BMS-986506 in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC)
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 11, 2026 · NCT07195682Open-Label Phase 1/2 Study of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 3, 2026 · NCT07300241Inulin Gel in Combination With Ipilimumab and Nivolumab for the Treatment of Metastatic or Locally Advanced Kidney Cell Cancer, ICON Trial
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Jul 31, 2026 · NCT06866262Effects of Belzutifan on 89Zr-DFO-girentuximab PET Uptake in Patients With Renal Cell Carcinoma (RCC)
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jul 30, 2026 · NCT07179770Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Jul 28, 2026 · NCT05263050Zanzalintinib for Metastatic Clear Cell Renal Cell Carcinoma With Bone Metastases
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Jul 27, 2026 · NCT07043608Imaging of Solid Tumors Using 18F-TRX
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jul 23, 2026 · NCT06942104Immunotherapy (Nivolumab and Ipilimumab) With and Without a Live Biotherapeutic Product (EXL01) for the Treatment of Metastatic Renal Cell Cancer
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jul 16, 2026 · NCT07128680Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Jun 11, 2026 · NCT07383441VSV-IFNβ-NIS With Ipilimumab and Nivolumab for the Treatment of Advanced or Metastatic Clear Cell Renal Cell Carcinoma
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Jun 5, 2026 · NCT07510334Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform
RecruitingObservational study
Ages 18 and older · All sexes · Updated Mar 12, 2026 · NCT06349642Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy With or Without Surgery to Remove the Kidney in Metastatic Kidney Cancer, the PROBE Trial
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 9, 2025 · NCT04510597CBM588 Capsules in Combination With Nivolumab and Ipilimumab for the Treatment of Advanced Stage Kidney Cancer
RecruitingPhase 1
Ages 18 and older · All sexes · Updated May 30, 2024 · NCT06399419From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.